CRISPR Therapeutics AG
Key Metrics
- Previous Close
- $40.15
- 52-Week Range
- $39.80 – $63.45
- Market Cap
- $3.90B
- P/E (TTM)
- —
- EPS (TTM)
- -4.73
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 2.36
- PEG Ratio
- —
- Return on Equity
- -25.60%
- Return on Assets
- -13.49%
- Gross Margin
- 0.00%
- Operating Margin
- -2058.55%
- Profit Margin
- 0.00%
- Current Ratio
- 16.21
- Debt/Equity
- 0.47
- Total Debt
- $779.83M
- Free Cash Flow
- $-215.40M
- Revenue Growth
- 1325.10%
- Earnings Growth
- —
- Enterprise Value
- $2.41B
Market Snapshot
About
CRISPR Therapeutics AG is a gene editing company focused on developing transformative medicines using CRISPR/Cas9 technology. Headquartered in Zug, Switzerland with U.S. operations in Cambridge, Massachusetts, the company is advancing a diverse portfolio of programs in areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. CRISPR Therapeutics gained FDA approval for Casgevy (exagamglogene autotemcel) in 2023, the first CRISPR-based gene therapy approved in the United States. The company maintains strategic partnerships with Vertex Pharmaceuticals and other leading healthcare organizations.